BioStock: Regulatory approval and up-listing for Cyxone

Activity is high in Cyxone. The biotechnology company recently received approval to start a phase II study in Poland with Rabeximod in patients suffering from moderate Covid-19. They have also announced the intention to apply for listing of their share on Nasdaq Stockholm's main list. BioStock reached out to CEO Tara Heitner, who shares her thoughts on the timing of the up-listing and how Rabeximod can open up for the treatment of respiratory diseases, beyond Covid-19, caused by viral infections.

Read the full interview with Tara Heitner at biostock.se:

https://www.biostock.se/en/regulatory-approval-and-up-listing-for-cyxone/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/